
Lundbeck reports Phase II success for asedebart in Cushing’s disease
Lundbeck’s investigational antibody asedebart has shown promise in treating Cushing’s disease, with early Phase II trial results indicating successful normalization of urinary free cortisol levels in the vast majority of evaluable patients, according to data presented at the 2026 Endocrine Society’s Annual Meeting in Chicago.






















